Ascletis Pharma to Present ASC30 and ASC47 Study Results at ADA Scientific Sessions

Ascletis Pharma will present poster presentations on its oral GLP-1R agonist ASC30 and adipose-targeted weight loss drug candidate ASC47 at the 85th Scientific Sessions of American Diabetes Association (ADA) in Chicago. ASC30 demonstrated positive results in a first-in-human single ascending dose study, while ASC47 showed superior weight loss when combined with semaglutide in preclinical models. The ADA is a nonprofit organization dedicated to preventing and curing diabetes and improving the lives of those affected.

Ascletis Pharma Inc. (HKEX: 1672) has announced that it will present poster presentations on its oral GLP-1R agonist ASC30 and adipose-targeted weight loss drug candidate ASC47 at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, U.S. The presentations will take place on June 22, 2025, from 12:30 PM to 1:30 PM (Chicago Time), corresponding to Monday, June 23, 2025, from 1:30 AM to 2:30 AM (Beijing Time).

ASC30, an investigational GLP-1R biased small molecule agonist, demonstrated positive results in a first-in-human single ascending dose study. The study, titled "ASC30, an Oral GLP-1R Biased Small Molecule Agonist in Participants with Obesity—A First-in-Human Single Ascending Dose Study," will be presented as a poster in the General Poster Session at Poster Hall (Hall F1) [1].

ASC47, an adipose-targeted, ultra-long-acting subcutaneously injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, showed superior weight loss when combined with semaglutide in preclinical models. The study, titled "ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model," will also be presented as a poster in the General Poster Session at Poster Hall (Hall F1) [1].

The ADA, established in 1940, is a nonprofit organization dedicated to preventing and curing diabetes and improving the lives of those affected. Its annual Scientific Sessions set the agenda for clinical practice and research innovation. This year's sessions will be held in Chicago, U.S., from June 20 to 23, 2025 [2].

Ascletis Pharma Inc. is an innovative R&D-driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to GMP manufacturing. The company is focused on metabolic diseases by addressing unmet medical needs from a global perspective [1].

References:
[1] https://www.prnewswire.com/news-releases/ascletis-announces-poster-presentations-on-the-study-results-of-asc30-and-asc47-at-the-85th-scientific-sessions-of-american-diabetes-association-ada-302475088.html
[2] https://www.gurufocus.com/news/2907435/metavia-announces-poster-presentation-on-da1241-at-the-adas-85th-scientific-sessions-mtva-stock-news